Cigna Group stock trades steadily as The Cigna Group highlights 2025 growth targets and recent earnings trajectory

Cigna Group (ISIN US1255231003) is a major US health services company whose Cigna Group stock is listed on the New York Stock Exchange and closely watched for its combination of insurance underwriting and health services earnings power. In its most recent full-year report for 2024, the group reported revenue in excess of $200 billion, with year-on-year growth versus 2023 in the high single-digit range, framing how the company sees its earnings base as it outlines targets for 2025. The Cigna Group has also underlined long-term earnings per share ambitions for the 2021 to 2025 period, providing investors with a framework that links near-term medical cost trends with multi-year capital deployment and share repurchases.

Revenue above $200 billion

According to Cigna Group's published annual results for 2024, total consolidated revenue exceeded $200 billion, reflecting an increase compared with 2023 driven largely by growth in the Evernorth health services division and the US medical insurance business. In the prior year 2023, The Cigna Group had already reported revenue above $190 billion, so the progression into 2024 illustrates high single-digit percentage growth over the period even as the company managed its medical cost ratios and pricing across commercial and government-related contracts. For investors in Cigna Group stock, the scale of this revenue base is central because it anchors the earnings per share trajectory and supports the company's capacity to fund dividends and share repurchases.

Looking at operating performance, Cigna Group's health services segment, branded Evernorth, has been a key contributor to recent growth. Over the last reported year, Evernorth service revenues increased versus the prior period, supported by expansion in pharmacy benefit management volumes and demand for integrated care management solutions. The Cigna Group highlighted that this non-insurance business diversifies its earnings and helps smooth volatility in medical underwriting results, an aspect that can make Cigna Group stock attractive to investors seeking exposure to both fee-based and risk-based health revenues. The interplay between the insurance book and the Evernorth health services franchise is increasingly important for understanding the company's consolidated margin profile.

EPS targets for 2025 period

The Cigna Group has previously set out long-term earnings per share ambitions for the 2021 to 2025 period, indicating that it aims to deliver mid-teens annual EPS growth over those years on an adjusted basis. In practical terms, this means that if adjusted EPS was near the mid-teens level in 2021, the company is targeting to roughly double that figure by 2025 through a combination of organic revenue growth, disciplined underwriting, expansion in Evernorth services, and capital allocation including share repurchases. For shareholders, such EPS guidance gives a metric against which to evaluate how Cigna Group stock trades relative to its earnings potential and broader health insurance peers.

Within its recent guidance discussions, The Cigna Group has also referred to expected consolidated medical care ratios and operating margins in its health insurance businesses. In the latest annual period, the company reported a medical care ratio within a relatively narrow band around the mid-eighties percent level, implying that claims costs versus premium revenues have been broadly in line with expectations. This compares with prior-year levels that were similar, underscoring that the insurer has managed to maintain stability in medical cost trends even amid changing utilization patterns. For investors, the relationship between these ratios and premium pricing is a key determinant of how the earnings base will evolve between 2024 and 2025.

Evernorth health services role

The Cigna Group's Evernorth health services division is a core part of the company’s strategy and has become increasingly prominent in its revenue and earnings mix. Evernorth brings together pharmacy benefit management, care coordination, behavioral health, and other services that generate fee-based income rather than insurance underwriting profits. In the most recent reporting period, Evernorth contributed tens of billions of dollars to consolidated revenue, marking a clear increase compared with its contribution several years ago when the segment was smaller before the full integration of acquired assets. For Cigna Group stock, the rising share of earnings from Evernorth is significant because it can reduce reliance on traditional commercial medical insurance cycles.

The company has emphasized that Evernorth’s revenue growth has been supported by new client wins, expanded services for existing clients, and the ongoing need for cost management across the US healthcare system. This strategic positioning allows The Cigna Group to capture value from managing pharmacy trends and complex care pathways, while also providing data and analytics tools to employers, health plans, and government programs. Investors often compare Evernorth’s performance with other integrated health services businesses in the sector, as it provides a way to benchmark Cigna Group stock against peers that also operate pharmacy and care management platforms.

Medical segment and membership metrics

On the insurance side, The Cigna Group reports results for its US medical business, which includes commercial employer-sponsored plans, individual coverage, and certain government-related offerings. Over the latest full year, medical membership levels were in the tens of millions across the combined portfolio, reflecting modest growth compared with the prior year as the company added new accounts and retained existing relationships. While precise membership figures are subject to quarterly changes, the company’s disclosures show that membership growth has been concentrated in key employer segments and select individual products where Cigna believes it can compete on both price and network breadth.

Medical premium revenue has moved broadly in line with membership and pricing trends, with The Cigna Group indicating that year-on-year premium growth in 2024 was mid single-digit to high single-digit depending on specific segments. This compares with similar growth ranges in 2023, illustrating that the insurer has been able to grow the top line at a pace that supports its EPS ambitions while managing medical cost ratios. For investors evaluating Cigna Group stock, the stability of this revenue progression is important, because health insurance businesses can be sensitive to shifts in utilization, regulatory changes, and competitive dynamics.

Capital deployment and share repurchases

Cigna Group has historically used share repurchases and dividends as key elements of its capital deployment strategy, alongside debt reduction and investments in growth. Over the span from 2021 to 2024, the company has returned many billions of dollars to shareholders through buybacks, which in turn support earnings per share growth by reducing the average share count. The Cigna Group has also indicated in its investor materials that it intends to continue using repurchases as a flexible tool to balance growth investment and shareholder returns, subject to regulatory and rating agency considerations. This capital deployment framework is a relevant factor for Cigna Group stock valuation discussions.

Debt management has also been part of the story. Cigna Group carries a significant level of corporate debt linked to its acquisitions and investments in health services platforms, but over recent years it has taken steps to manage leverage ratios to levels consistent with its targeted credit ratings. The company’s guidance often refers to maintaining a disciplined balance sheet and using excess capital to fund both organic and inorganic growth, such as bolt-on acquisitions or technology investments that can strengthen Evernorth and other service offerings. Investors following Cigna Group stock therefore pay attention to leverage metrics and interest expense trends as part of their broader assessment of financial health.

Representative product: integrated health plans

One representative product line for The Cigna Group is its integrated health plan offerings that combine medical benefits with pharmacy coverage and behavioral health support. These plans are marketed to large employers seeking to manage total health costs while supporting employee wellbeing, and they often include access to Evernorth’s pharmacy benefit management and care coordination services. Over recent reporting periods, Cigna has indicated that integrated plans have contributed meaningfully to its medical membership and premium base, with employers adopting these products to leverage combined care management features and consolidated reporting. For the company, such offerings help deepen client relationships and create cross-selling opportunities between insurance and health services.

Cigna Group stock and market context

Cigna Group stock trades on the New York Stock Exchange under the ticker CI, and its share price reflects both the underlying health insurance and health services earnings trajectory and broader sector sentiment. Market participants compare the valuation of Cigna Group stock with other large US health insurers and integrated services companies, looking at metrics such as price-to-earnings ratios and expected EPS growth rates. Over the last year, the shares have generally moved in tandem with major US health insurance peers, responding to news about medical cost trends, regulatory developments, and quarterly earnings data. Because detailed real-time price information can change frequently throughout each trading day, investors typically monitor up-to-date quotes via their trading platforms or exchange data.